Fed. Trade Comm'n v. Omics Grp. Inc.

374 F. Supp. 3d 994
CourtDistrict Court, D. Nevada
DecidedMarch 29, 2019
DocketCase No.: 2:16-cv-02022-GMN-VCF
StatusPublished
Cited by3 cases

This text of 374 F. Supp. 3d 994 (Fed. Trade Comm'n v. Omics Grp. Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fed. Trade Comm'n v. Omics Grp. Inc., 374 F. Supp. 3d 994 (D. Nev. 2019).

Opinion

Gloria M. Navarro, Chief Judge *1002Pending before the Court is the Motion for Summary Judgment, (ECF No. 86 ), filed by Plaintiff Federal Trade Commission ("the FTC"). Defendants OMICS Group Inc. ("OMICS"), iMedPub LLC ("iMedPub"), Conference Series LLC ("Conference Series"), and Srinubabu Gedela ("Gedela") (collectively "Defendants") filed a Response, (ECF No. 110 ), and the FTC filed a Reply, (ECF No. 115 ). Also, before the Court is the Motion for Summary Judgment, (ECF No. 89 ), filed by Defendants. The FTC filed a Response, (ECF No. 97 ),1 and Defendants filed a Reply, (ECF No. 107 ). For the reasons discussed herein, the FTC's Motion for Summary Judgment is GRANTED , and Defendants' Motion for Summary Judgment is DENIED.

I. BACKGROUND

A. Overview

The FTC brings this action pursuant to Section 5(a) of the FTC Act, 15 U.S.C. § 45(a), alleging that Defendants engaged in unfair and deceptive practices with respect to the publication of online academic journals and organization of scientific conferences. (See Compl., ECF No. 1 ). Defendants claim to operate hundreds of online academic journals on a wide variety of topics, including medicine, chemistry, nursing, engineering, and genetics. (Id. ¶ 20); (Gedela Decl. ¶¶ 14-15, Ex. 1 to Defs.' MSJ, ECF No. 89-1 ). In order to persuade consumers to submit articles for publication, the FTC alleges that Defendants make numerous misrepresentations regarding the nature and reputation of their journals. (Compl. ¶¶ 11, 12). The FTC also alleges that Defendants fail to disclose the significant fees associated with their publishing services. (Id. ¶ 13). Finally, the FTC alleges that Defendants make numerous misrepresentations in connection with the marketing of their scientific conferences. (Id. ¶ 14).

The FTC asserts that Defendants OMICS, iMedPub, and Conference Series (collectively "Corporate Defendants") have operated as a common enterprise in violating Section 5(a) and therefore are jointly and severally liable. (Id. ¶ 10). The FTC further asserts that Gedela has "formulated, directed, controlled, had the authority to control, or participated in the acts and practices of the Corporate Defendants that constitute the common enterprise." (Id. ). Based on these allegations, the FTC initiated this action against Defendants on August 25, 2016. On September 29, 2017, the Court granted the FTC's request for a preliminary injunction, requiring Defendants to preserve records, provide financial accounting to the FTC, and refrain from engaging in deceptive practices. (Prelim. Inj. Order, ECF No. 46 ). The parties now submit their respective motions for summary judgment on the FTC's unfair and deceptive practices claim.

B. Background on Academic Publishing2

1) Traditional Model vs. Open Access

Academic or scholarly journals are peer-reviewed publications that focus on a *1003particular academic or scientific discipline. (See SJX18 Backus Decl. ¶ 5, Ex. 18 to FTC's MSJ, ECF No. 86-18 ).3 These publications are comprised of articles, which typically take the form of "original research, review articles, commentaries, or clinical case studies." (Id. ).

Under the traditional model, publishers charge libraries and individuals "user subscription fees" to gain access to the published material. (Id. ¶ 6). The articles remain accessible to the extent users remain subscribed to the journal. (See id. ). In contrast, under the newer "open access" model, journals make their content available to the public at no cost, subsidizing their operations primarily through author-funded publication fees. (Id. ¶ 7); (Gedela Decl. ¶ 9, Ex. 1 to Defs.' MSJ). By removing price and permission barriers, this model increases access to a broader community. (SJX18 Backus Decl. ¶ 9); (Gedela Decl. ¶ 10).

2) Peer Review

"Peer-review" is the process of subjecting an author's scholarly work, research, or ideas to the scrutiny of qualified experts in the same field prior to publishing in a journal. (SJX18 Backus Decl. ¶ 12). When an author submits their work for publication, the journal makes an initial determination regarding whether to accept the article for peer review or reject it outright. (Id. ). If accepted, authors are expected to respond to peer reviewer commentary, implement recommendations, and, if necessary, justify the rejection of any proposed revisions. (See id. ¶¶ 14-15). The peer-review process typically takes several months. (Id. ). Prior to publishing, authors are usually required to sign a publication agreement that gives the journal the right to publish the submitted article. (Id. ¶ 14).

3) Impact Factors

In the academic publishing industry, a journal's "impact factor" is often used as an objective measure of the prestige or relative importance of a journal in its field. (Id. ¶ 15). "Impact factor" typically measures the average number of scholarly citations that articles receive in a published journal. (See id. ¶ 16). A higher impact factor indicates a more reputable journal. (Id. ¶ 15). Amongst those in the industry, the term is specifically understood to mean the proprietary citation measure calculated and published by Thomson Reuters in its Journal Citation Reports. (Id. ¶ 16).4 A journal must be indexed by Thomson Reuters in either its Science Citation Index Expanded or its Social Sciences Citation Index to receive an impact factor. (Id. ).

4) Indexing

Aside from impact factors, "indexing" also serves as an indicator of a journal's reputation. (Id. ¶¶ 17-22). The United States National Library of Medicine ("NLM") produces and manages three freely accessible bibliographical resources: PubMed, Medline, and PubMed Central. (SJX11 Admissions Nos. 42, 43). Journals must apply for inclusion in Medline and *1004PubMed Central, upon which time an NIH-chartered advisory committee reviews the submission. (See id. ). Due to the selective nature of these indexes, a journal's inclusion is considered indicative of a journal's quality. (

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Davis v. Saidro
S.D. California, 2021
Gomez v. Madden
S.D. California, 2020

Cite This Page — Counsel Stack

Bluebook (online)
374 F. Supp. 3d 994, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fed-trade-commn-v-omics-grp-inc-nvd-2019.